IDT specialises in the research and development of novel diagnostics and therapeutics that target unmet needs in the field of cancer. IDT has built a strong global reputation in the research and commercialisation of novel cancer diagnostics.

Attached below are information on what our current work programs are focussed on as well as up-to-date investor documents. If you and your company are interested in investing in one of our next projects or wish to find out more information send your request to:

Ran GTPase Inhibitors[1]

RanDx Diagnostics[2]

Ran GTP Inhibitors A New Class of Cancer Therapeutics May 17 copy